CN1382062A - 通过多位点结合的寻靶多体造影剂 - Google Patents

通过多位点结合的寻靶多体造影剂 Download PDF

Info

Publication number
CN1382062A
CN1382062A CN00813045A CN00813045A CN1382062A CN 1382062 A CN1382062 A CN 1382062A CN 00813045 A CN00813045 A CN 00813045A CN 00813045 A CN00813045 A CN 00813045A CN 1382062 A CN1382062 A CN 1382062A
Authority
CN
China
Prior art keywords
iem
contrast agent
tbm
target
framework
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00813045A
Other languages
English (en)
Chinese (zh)
Inventor
R·B·劳弗
T·J·麦克默瑞
S·迪马
A·科沃杰伊
J·阿梅迪奥
P·卡拉文
张昭达
S·奈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epix Pharmaceuticals Inc
Original Assignee
Epix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Pharmaceuticals Inc filed Critical Epix Pharmaceuticals Inc
Publication of CN1382062A publication Critical patent/CN1382062A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
CN00813045A 1999-07-29 2000-07-28 通过多位点结合的寻靶多体造影剂 Pending CN1382062A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14641499P 1999-07-29 1999-07-29
US16365099P 1999-11-04 1999-11-04
US60/146,414 1999-11-04
US60/163,650 1999-11-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2004100567047A Division CN1626246A (zh) 1999-07-29 2000-07-28 通过多位点结合的寻靶多体造影剂

Publications (1)

Publication Number Publication Date
CN1382062A true CN1382062A (zh) 2002-11-27

Family

ID=26843871

Family Applications (2)

Application Number Title Priority Date Filing Date
CN00813045A Pending CN1382062A (zh) 1999-07-29 2000-07-28 通过多位点结合的寻靶多体造影剂
CNA2004100567047A Pending CN1626246A (zh) 1999-07-29 2000-07-28 通过多位点结合的寻靶多体造影剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2004100567047A Pending CN1626246A (zh) 1999-07-29 2000-07-28 通过多位点结合的寻靶多体造影剂

Country Status (20)

Country Link
US (2) US6652835B1 (enExample)
EP (1) EP1210124A2 (enExample)
JP (2) JP2003505519A (enExample)
KR (1) KR20020057946A (enExample)
CN (2) CN1382062A (enExample)
AU (1) AU6386000A (enExample)
BR (1) BR0013171A (enExample)
CA (1) CA2384565A1 (enExample)
CZ (1) CZ2002343A3 (enExample)
EA (1) EA200200220A1 (enExample)
HK (1) HK1048952A1 (enExample)
HU (1) HUP0202635A3 (enExample)
IL (1) IL147854A0 (enExample)
IS (1) IS6241A (enExample)
MX (1) MXPA02001017A (enExample)
NO (1) NO20020474L (enExample)
NZ (1) NZ517017A (enExample)
PL (1) PL353336A1 (enExample)
WO (1) WO2001008712A2 (enExample)
YU (1) YU6502A (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101222878B (zh) * 2005-07-13 2012-12-26 佐治亚州立大学研究基金会 显像剂及其制备方法

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW319763B (enExample) * 1995-02-01 1997-11-11 Epix Medical Inc
US6713045B1 (en) 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
CA2309749A1 (en) 1997-11-17 1999-05-27 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
WO2001009188A1 (en) * 1999-07-29 2001-02-08 Dyax Corp. Binding moieties for fibrin
US6652835B1 (en) * 1999-07-29 2003-11-25 Epix Medical, Inc. Targeting multimeric imaging agents through multilocus binding
US6673333B1 (en) 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
WO2002006287A2 (en) 2000-07-17 2002-01-24 California Institute Of Technology Macrocyclic mri contrast agents
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
TWI240632B (en) * 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
JP2005529839A (ja) * 2001-10-16 2005-10-06 エピックス メディカル， インコーポレイテッド 脈管内病変の検出および処置
US7504364B2 (en) * 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
DE10231799B4 (de) * 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
US7344704B2 (en) 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
US20050136483A1 (en) * 2003-09-03 2005-06-23 Receptors Llc Nanodevices employing combinatorial artificial receptors
US20040137481A1 (en) * 2002-09-16 2004-07-15 Receptors Llc Artificial receptor building blocks, components, and kits
US20050037381A1 (en) * 2002-09-16 2005-02-17 Receptors Llc Artificial receptors, building blocks, and methods
US20060057625A1 (en) * 2002-09-16 2006-03-16 Carlson Robert E Scaffold-based artificial receptors and methods
US7469076B2 (en) * 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
US20060051802A1 (en) * 2002-09-16 2006-03-09 Receptors Llc Artificial receptors, building blocks, and methods
US20050037429A1 (en) * 2003-03-28 2005-02-17 Receptors Llc Artificial receptors including reversibly immobilized building blocks and methods
EP1613737A4 (en) * 2003-03-28 2008-12-03 Receptors Llc ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
CN1795015A (zh) 2003-05-23 2006-06-28 埃匹克斯医药品股份有限公司 螯合配位体和造影剂的光学纯和光学富集异构体
DE10325752A1 (de) * 2003-06-06 2004-12-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Lektin-Konjugate
AR047692A1 (es) * 2003-07-10 2006-02-08 Epix Medical Inc Imagenes de blancos estacionarios
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7557577B2 (en) * 2003-12-08 2009-07-07 Siemens Aktiengesselschaft Water-soluble paramagnetic substance reducing the relaxation time of the coolant in an MRI system
WO2005079274A2 (en) * 2004-02-12 2005-09-01 Mount Sinai School Of Medicine Magnetic resonance imaging of atherosclerotic plaque
WO2006028930A2 (en) * 2004-09-03 2006-03-16 Receptors Llc Combinatorial artificial receptors including tether building blocks on scaffolds
WO2006027244A2 (en) * 2004-09-10 2006-03-16 Bracco Imaging S.P.A. Paramagnetic metal polyamino complexes for mri visualization of internalized polynucleotides
EP1789792A2 (en) 2004-09-11 2007-05-30 Receptors LLC Combinatorial artificial receptors including peptide building blocks
WO2006056227A1 (en) * 2004-11-27 2006-06-01 Eberhard-Karls- Universität Tübingen Universitätsklinikum Conjugates comprising the active agent and flanking or branched-chain peptides
DE102004062258B3 (de) * 2004-12-23 2006-01-05 Schering Ag Hydroxypyridinon-Derivate, deren Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
EP1836239B1 (en) 2005-01-13 2008-10-29 Cinvention Ag Composite materials containing carbon nanoparticles
US20060275217A1 (en) * 2005-05-06 2006-12-07 Caravan Peter D Chemical exchange saturation transfer contrast agents
AU2006303324A1 (en) * 2005-10-18 2007-04-26 Cinvention Ag Thermoset particles and methods for production thereof
EP1955071A4 (en) 2005-10-28 2009-03-18 Invitrogen Corp ASSAYS OF ACTIVITY KINASE AND UBIQUITINATION
US20070293656A1 (en) 2005-12-29 2007-12-20 Epix Pharmaceuticals, Inc. Collagen binding peptides
US20080044358A1 (en) * 2006-08-17 2008-02-21 Vincent Jacques Methods for lymph system imaging
EP2156186A4 (en) * 2007-05-03 2010-11-03 Tethys Bioscience Inc BINDING REAGENTS WITH SMALL EPITOP BINDING MOLECULES
DE102007028090A1 (de) 2007-06-12 2008-12-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Aktivierbare diagnostische und therapeutische Verbindung
WO2009023813A1 (en) * 2007-08-15 2009-02-19 Applied Soil Water Technologies Llc Metals recovery from mining heap leach ore
US20090214436A1 (en) * 2008-02-18 2009-08-27 Washington University Dichromic fluorescent compounds
US8722020B2 (en) 2010-03-31 2014-05-13 General Electric Company Hydroxylated contrast enhancement agents
US8362281B2 (en) 2010-03-31 2013-01-29 General Electric Company Intermediates for hydroxylated contrast enhancement agents
US8765977B2 (en) 2010-03-31 2014-07-01 General Electric Company Hydroxylated contrast enhancement agents and imaging method
EP2806781B1 (en) 2012-01-23 2018-03-21 Washington University Goggle imaging systems and methods
US9849201B2 (en) 2013-05-03 2017-12-26 Washington University Homing agents
US10806804B2 (en) 2015-05-06 2020-10-20 Washington University Compounds having RD targeting motifs and methods of use thereof
US10301358B2 (en) 2015-06-29 2019-05-28 Collagen Medical, LLC Collagen imaging compositions
WO2017027834A1 (en) 2015-08-13 2017-02-16 The General Hospital Corporation Manganese-based chelate conjugates for molecular mr imaging
EP3576801A4 (en) 2017-02-02 2020-12-16 The University of Akron FUNCTIONALIZED POLY (PROPYLENE FUMARATE) POLYMERS MANUFACTURED BY CYCLE OPENING POLYMERIZATION USING MAGNESIUM CATALYSTS
EP4072598A4 (en) 2019-12-13 2024-02-21 Washington University Near infrared fluorescent dyes, formulations and related methods

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880008A (en) 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4777957A (en) * 1985-06-14 1988-10-18 General Electric Company Method for measuring and imaging fluid flow
EP0247156B1 (en) * 1985-11-18 1993-06-23 Access Pharmaceuticals Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
DE3786000T3 (de) 1986-08-18 1997-08-21 Dow Chemical Co Conjugate dichter Sterne.
US5011686A (en) * 1987-09-21 1991-04-30 Creative Biomolecules, Inc. Thrombus specific conjugates
GB8808305D0 (en) * 1988-04-08 1988-05-11 Nycomed As Compositions
US5914095A (en) 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
ATE166864T1 (de) 1989-10-23 1998-06-15 Nycomed Salutar Inc Mehrzähnige metall-chelatierende verbindungen
GB9320277D0 (en) 1993-10-01 1993-11-17 Nycomed Salutar Inc Chelants
US5650133A (en) * 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
US5631329A (en) 1990-08-27 1997-05-20 Dendritech, Inc. Process for producing hyper-comb-branched polymers
WO1992021017A1 (en) * 1991-05-23 1992-11-26 Unger Evan C Liposoluble compounds for magnetic resonance imaging
JP2894879B2 (ja) * 1991-10-04 1999-05-24 日本メジフィジックス株式会社 診断用造影剤
US5522390A (en) * 1991-11-21 1996-06-04 U.S. Philips Corporation Magnetic resonance imaging method
US5637759A (en) 1992-07-30 1997-06-10 The Regents Of The University Of California Metal-ligating amino acid derivatives for MRI and for peptide synthesis
DE69332203T2 (de) 1992-10-02 2003-05-28 Diatide, Inc. Multimerische mehrzweckwirkstoffe gegen thrombose
US5726304A (en) 1992-10-30 1998-03-10 The University Of British Columbia Porphocyanine and CNC-expanded porphyrins
US5401493A (en) * 1993-03-26 1995-03-28 Molecular Biosystems, Inc. Perfluoro-1H,-1H-neopentyl containing contrast agents and method to use same
US5579767A (en) * 1993-06-07 1996-12-03 Prince; Martin R. Method for imaging abdominal aorta and aortic aneurysms
GB9314499D0 (en) * 1993-07-12 1993-08-25 Nycomed Imaging As Method
GB9318550D0 (en) 1993-09-07 1993-10-20 Nycomed Salutar Inc Chelants
DE4344460A1 (de) * 1993-12-22 1995-06-29 Schering Ag Metallkomplexe von dendrimeren Makromolekülen, diese enthaltende diagnostische Mittel sowie Verfahren zur Herstellung der Komplexe und Mittel
IT1270994B (it) 1994-03-18 1997-05-26 Bracco Spa Macromolecole ramificate a struttura poliossialchilica e loro usi
WO1995027705A1 (en) 1994-04-08 1995-10-19 Bracco International B.V. Aromatic amide compounds and metal chelates thereof
GB9407812D0 (en) 1994-04-20 1994-06-15 Nycomed Salutar Inc Compounds
DE4425857A1 (de) * 1994-07-07 1996-01-11 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zur ihrer Herstellung und diese enthaltende pharmazeutische Mittel
WO1998053855A1 (en) * 1997-05-30 1998-12-03 Alliance Pharmaceutical Corp. Methods and apparatus for monitoring and quantifying the movement of fluid
US6232295B1 (en) 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
TW319763B (enExample) * 1995-02-01 1997-11-11 Epix Medical Inc
DE19518222A1 (de) 1995-05-11 1996-11-14 Schering Ag Verwendung von polymeren Kontrastmittel mittleren Molekulargewichts zur Differenzierung von benignen und malignen Tumoren mittels moderner bildgebender Verfahren
DE19521945A1 (de) 1995-06-12 1996-12-19 Schering Ag Kaskadenpolymere mit Iodaromaten
DE19525924A1 (de) * 1995-07-04 1997-01-09 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US5919442A (en) 1995-08-11 1999-07-06 Dendritech, Inc. Hyper comb-branched polymer conjugates
IT1277596B1 (it) 1995-09-15 1997-11-11 Bracco Spa Composti macromolecolari di tipo dendrimerico
US6638508B2 (en) * 1995-12-21 2003-10-28 Yeda Research And Development Co., Ltd. Modified avidin-type molecules as targeting agents for the liver and cells of the reticuloendothelial system
IT1283218B1 (it) * 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
PT907379E (pt) 1996-04-01 2004-09-30 Epix Medical Inc Agentes de contraste bioactivados para imagiologia de diagnostico
WO1997041856A1 (en) 1996-05-08 1997-11-13 Massachusetts Institute Of Technology ORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO)
DE19641197C2 (de) * 1996-09-24 1999-02-18 Schering Ag Ionenpaare und ihre Verwendung als Kontrastmittel
NZ500273A (en) * 1997-03-18 2001-12-21 Nihon Schering Kabushiki Kaish Gadolinium (Gd) polymer MRI contrast agent responsive to environmental changes
DE19731300C1 (de) * 1997-07-11 1999-01-21 Schering Ag Perfluoralkylgruppenhaltige Trijodaromaten, Verfahren zu deren Herstellung und deren Verwendung als Kontrastmittel
US6073042A (en) * 1997-09-25 2000-06-06 Siemens Medical Systems, Inc. Display of three-dimensional MRA images in which arteries can be distinguished from veins
CA2309749A1 (en) * 1997-11-17 1999-05-27 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6112112A (en) * 1998-09-18 2000-08-29 Arch Development Corporation Method and system for the assessment of tumor extent in magnetic resonance images
US6342598B1 (en) * 1998-11-26 2002-01-29 Bracco International B.V. Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6399578B1 (en) * 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
WO2001009188A1 (en) * 1999-07-29 2001-02-08 Dyax Corp. Binding moieties for fibrin
US6652835B1 (en) * 1999-07-29 2003-11-25 Epix Medical, Inc. Targeting multimeric imaging agents through multilocus binding
EP1379885A4 (en) * 2001-01-05 2005-07-06 Univ Duke CONTRAST REINFORCING AGENT FOR MAGNETIC RESONANCE IMAGING
US6459264B1 (en) * 2001-02-22 2002-10-01 Mayo Foundation For Medical Education And Research Real-time embedded magnetic resonance fluoroscopy
JP2005534697A (ja) * 2002-08-06 2005-11-17 エピックス ファーマシューティカルズ， インコーポレイテッド ペプチド凝集体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101222878B (zh) * 2005-07-13 2012-12-26 佐治亚州立大学研究基金会 显像剂及其制备方法

Also Published As

Publication number Publication date
KR20020057946A (ko) 2002-07-12
HK1048952A1 (zh) 2003-04-25
NO20020474L (no) 2002-03-27
WO2001008712A2 (en) 2001-02-08
US6652835B1 (en) 2003-11-25
CN1626246A (zh) 2005-06-15
NO20020474D0 (no) 2002-01-29
HUP0202635A2 (hu) 2002-11-28
CA2384565A1 (en) 2001-02-08
AU6386000A (en) 2001-02-19
HUP0202635A3 (en) 2006-03-28
BR0013171A (pt) 2002-05-28
IL147854A0 (en) 2002-08-14
PL353336A1 (en) 2003-11-17
EP1210124A2 (en) 2002-06-05
YU6502A (sh) 2005-06-10
IS6241A (is) 2002-01-18
JP2003505519A (ja) 2003-02-12
EA200200220A1 (ru) 2002-08-29
CZ2002343A3 (cs) 2002-08-14
WO2001008712A3 (en) 2002-03-14
MXPA02001017A (es) 2002-08-12
JP2003201258A (ja) 2003-07-18
US20040005274A1 (en) 2004-01-08
NZ517017A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
CN1382062A (zh) 通过多位点结合的寻靶多体造影剂
CN1177806C (zh) 可延长血液潴留的诊断成像用造影剂
CN101305006B (zh) 含有短氨基醇链的化合物和用于医学成像的金属络合物
JP4298501B2 (ja) ペプチドに基づく多量体標的化造影剤
TWI238722B (en) Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy
CN1622830A (zh) 肽基化合物
CN1215341A (zh) 生物活化的诊断成像造影剂
CN1189779A (zh) 级联聚合物的配合物,其制备方法以及包含该配合物的药剂
CN101068577A (zh) 施陶丁格连接在用于显像和治疗的显像和治疗目的试剂盒中的应用
CN108368067A (zh) 二聚造影剂
EP2257316B1 (en) Contrast agents, methods for preparing contrast agents, and methods of imaging
US9200017B2 (en) Multimodal imaging of fibrin
KR102464647B1 (ko) 자기 공명 영상화에 사용하기 위한 높은 이완도 가돌리늄 킬레이트 화합물
CN109963838A (zh) 二聚造影剂
CN101065152A (zh) 靶向尿激酶纤溶酶原激活物受体的造影剂
CN1668338A (zh) 包含全氟烷基的金属络合物在显影血管内血栓的mr显影中作为造影剂的应用
JP2001509796A (ja) 重合体
US9889213B2 (en) Multimodal imaging of fibrin
AU2005202428B2 (en) Targeting Multimeric Imaging Agents Through Multilocus Binding
TWI382851B (zh) 配位化合物及用於製備血池及目標化對比劑之金屬錯合物
HK1013915B (en) Cascade polymer complexes method of manufacture, and pharmaceutical agents containing them

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication